All companies
Visit website
BioEclipse Therapeutics
OperatingBioEclipse Therapeutics, Inc.
Technology · Founded 2006
Clinical-stage oncology company that uses platform technology to develop immuno-oncology therapeutics
Post-money valuation ⓘ
$29.0M
As of Apr 2022 · from BioEclipse Therapeutics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2022
Latest share price
$2.55
BioEclipse Therapeutics Common Stock 1 offering price
Financials
FY2019–FY2020 · from SEC filings · hover any figure for its source$0
−$2.4M
2019
$0
−$4.4M
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$2,415,736
-$4,391,188
Taxes paid
$0
$0
Balance sheet
Cash
$5,394,836
$2,331,499
Accounts receivable
$0
$0
Total assets
$5,839,337
$2,956,073
Short-term debt
$0
$75,862
Long-term debt
$0
$0
Total liabilities
$0
$75,862
Other
Headcount
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$29.0M
post-money
BioEclipse Therapeutics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.1MPost-money $29M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001780708Share price $2.55
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.